Collectively, manipulations mitigating the effects of various pro‐ageing factors have been proposed as potentially effective approaches for slowing or reversing the ageing process and B2M may be one of these therapeutic targets for age‐related diseases, including sarcopenia and dementia. This evidence concerns the gene B2M and sarcopenia.